Efectividad y seguridad de darunavir a largo plazo

Rubio, Rafael; Matarranz, Mariano; Bisbal, Otilia; Lagarde, María de; Domínguez, Lourdes.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 34(supl.1): 16-22, mayo 2016. graf, tab
Artículo en Español | IBECS (España) | ID: ibc-170755

Documentos relacionados

  1. The use of unboosted darunavir in the setting of ritonavir intolerance: three case reports.
  2. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
  3. Contemporary protease inhibitors and cardiovascular risk.
  4. Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-study.
  5. Presente y futuro de darunavir para el tratamiento de la infección por virus de la inmunodeficiencia humana
  6. Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain.
  7. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
  8. Sinus bradycardia induced by darunavir-ritonavir in a patient with acquired immunodeficiency syndrome.
  9. [Long-term safety and effectiveness of darunavir].
  10. Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study).